Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemo RT in Locally Advanced NSCLC Treated With IO (Durvalumab)

NCT04711330 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT04711330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04711330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemo RT in Locally Advanced NSCLC Treated With IO (Durvalumab)
Lead sponsor
Leiden University Medical Center
Phase
Observational
Overall status
Active, not recruiting
Start date
September 1, 2022
Completion date
October 2, 2025
Enrollment
126 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, non small cell lung cancer stage iii